Decreased level of endogenous secretory receptor for advanced glycation end-products in diabetes with concomitant hyperlipidemia
Language English Country Czech Republic Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24397807
DOI
10.33549/physiolres.932559
PII: 932559
Knihovny.cz E-resources
- MeSH
- Biomarkers blood MeSH
- Diabetes Mellitus, Type 2 blood diagnosis epidemiology MeSH
- Adult MeSH
- Hyperlipidemias blood epidemiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Glycation End Products, Advanced blood MeSH
- Receptor for Advanced Glycation End Products MeSH
- Receptors, Immunologic blood MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Biomarkers MeSH
- Glycation End Products, Advanced MeSH
- Receptor for Advanced Glycation End Products MeSH
- Receptors, Immunologic MeSH
Endogenous secretory receptor (esRAGE) for advanced glycation end-product (AGE) acts as decoy for AGEs. The AGE-to-esRAGE ratio was hypothesized to be implicated in diabetic vasculopathy. We investigated an association of esRAGE and methylglyoxal-adducts serum level, as well as AGE-to-esRAGE ratio in subpopulation of diabetic patients with or without concomitant hyperlipidemia and macrovascular disease in history. In diabetes with concomitant hyperlipidemia esRAGE was significantly decreased compared to hyperlipidemia with normal glucose metabolism (0.306+/-0.2 vs. 0.367+/-0.1; p=0.019) or diabetes alone (0.306+/-0.2 vs. 0.404+/-0.1; p=0.004). High AGE/esRAGE ratio, found in diabetic patients with hyperlipidemia, pointed to increased production of AGEs and low expression of esRAGE. In multivariable analysis adjusted for several confounding factors, increased AGE/esRAGE ratio was recognized as a high risk for vascular disease outcomes.
References provided by Crossref.org
